• Javier de Castro, Marina C Rodríguez, Vicenta S Martínez-Zorzano, Patricia Sánchez-Rodríguez, and Jesús Sánchez-Yagüe.
• From the Radiology Service and Lung Diseases Service, Santísima Trinidad Foundation Hospital, Salamanca, Spain; Department of Biochemistry, Genetics and Immunology, University of Vigo, Vigo, Spain; and Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain.
• Am. J. Clin. Pathol. 2014 Jul 1;142(1):111-20.

ObjectivesTo analyze the fatty acid profiles of erythrocyte total lipids from patients with advanced squamous cell lung carcinoma (SCC), lung adenocarcinoma (ADC), and small cell lung cancer (SCLC) and benign lung diseases (chronic obstructive pulmonary disease [COPD] and asthma) to reveal the fatty acids that could be used as lung cancer biomarkers.MethodsThirty, 20, 15, 17, and 19 patients with SCC, ADC, SCLC, COPD, and asthma, respectively, and 55 healthy participants were enrolled in our study. Fatty acid profiles were investigated using gas chromatography/mass spectrometry followed by receiver operating characteristic (ROC) curve analysis. Sialic acid (SA) and cytokeratins were measured by the thiobarbituric acid and immunoradiometric methods, respectively.ResultsAt least one of the main fatty acids might be used as a biomarker for every type of lung cancer: arachidonic (20:4n6), linoleic (18:2n6), and stearic (18:0) acids for ADC, SCC, and SCLC, respectively. These fatty acids showed diagnostic yields and operating characteristics similar to or higher than the commonly used SA or cytokeratin markers.ConclusionsFatty acids from erythrocyte total lipids might be used as diagnostic biomarkers of lung ADC, SCC, and SCLC. Their use in different aspects of the disease process needs to be explored.Copyright© by the American Society for Clinical Pathology.

32 keywords...

hide…